Company / Cash & Equivalents
Avalon GloboCare Corp. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$109.1K
FY2025
5-year range
$109.1K / $2.7M
FY2021-FY2025
Trend
-95.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $0 in FY2016 to $3M in FY2018.
Based on SEC 10-K filings.
$109,091 in FY2025 with a 5-year CAGR of -32.3%.
Declined from $285,400 to $109,091 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -62.0%
- 5-Year CAGR
- -32.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -32.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 95.9% year-over-year.
- Peak cash & equivalents was recorded in FY2018.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.96 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $109.1K | -95.9% |
| FY2024 | $2.7M | +831.4% |
| FY2023 | $285.4K | -85.7% |
| FY2022 | $2.0M | +146.5% |
| FY2021 | $807.5K | +5.6% |
| FY2020 | $764.9K | -66.0% |
| FY2019 | $2.3M | -25.6% |
| FY2018 | $3.0M | +4.9% |
| FY2017 | $2.9M | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026